Synthego, a leading supplier of CRISPR solutions, has entered a strategic licensing agreement with global biopharmaceutical company AstraZeneca. This agreement grants Synthego a global license to ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Perspective Therapeutics (CATX – Research Report) yesterday and ...

VG901 received FDA Rare Pediatric Disease Designation, potentially qualifying for a priority review voucher upon marketing ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Ginkgo Bioworks , which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize ...

Shares of Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat.com ...

The combined price per share and accompanying warrant was based in part upon the last reported sale price of the common ... Vor’s trem-cel therapy, which uses CRISPR/cas9 to edit the bone ...

Securities.io is not an investment adviser, and this does not constitute investment advice, financial advice, or trading advice. Securities.io does not recommend that any security should be bought, ...

Vor’s trem-cel therapy, which uses CRISPR/cas9 to edit the bone marrow of patients ... or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...